For many, morning sickness is a routine, albeit unpleasant, part of pregnancy. However, for a significant minority, it escalates into a debilitating medical crisis. A landmark genetic study has now identified the primary biological drivers behind hyperemesis gravidarum (HG) —an extreme form of nausea and vomiting that can lead to malnutrition, dehydration, and hospitalization.
Understanding Hyperemesis Gravidarum (HG)
While most pregnant individuals experience mild nausea, approximately 10.8% suffer from HG. This condition is far more than “morning sickness”; it is characterized by vomiting so severe that patients often cannot keep food or liquids down.
Until now, the medical community lacked FDA-approved treatments specifically for HG, and the underlying cause remained a subject of debate. Previous theories suggested that surges in pregnancy hormones—specifically hCG (human chorionic gonadotropin) and estrogen —were the culprits. However, this new research shifts the focus toward a different biological pathway.
The GDF15 Connection
Published in the journal Nature Genetics, the study—the largest of its kind—points to the GDF15 gene as the primary driver of the condition.
The research, led by Marlena Fejzo of the Keck School of Medicine at the University of Southern California, found that specific mutations in the GDF15 gene significantly increase the risk of HG. In some cases, a single rare mutation can increase a person’s risk tenfold.
Key Findings of the Study:
- A Universal Driver: By analyzing the genomes of nearly 11,000 people with HG and 420,000 without, researchers found that the GDF15 signal remained consistent across diverse populations, including those of European, Asian, African, and Latino descent.
- Beyond Hormones: The study found no genetic link to hCG or estrogen, effectively moving the scientific conversation away from the old “hormone sensitivity” theory.
- A Complex Web of Genes: Beyond GDF15, the team identified nine other genes associated with HG, suggesting the condition is a complex multi-pathway disease.
New Frontiers in Treatment
The identification of these genes opens the door to targeted pharmaceutical interventions. One of the most intriguing discoveries involves the TCF7L2 gene, which is a known risk factor for type 2 diabetes and regulates GLP-1 —the same hormone targeted by popular weight-loss drugs like Ozempic and Wegovy.
This connection suggests that the biological mechanisms regulating appetite and insulin may play a critical role in how the body responds during pregnancy. Other identified genes are linked to:
– Appetite regulation and wasting syndromes.
– Learning and memory, which researchers believe may influence the extreme food aversions common in HG sufferers.
Looking Ahead: Clinical Trials
The discovery is moving rapidly from the lab toward clinical application. This summer, researchers aim to launch a trial using metformin, a medication typically used for diabetes. Because metformin increases GDF15, the study will test whether administering it to patients before conception can “desensitize” them to the hormone, potentially preventing the onset of severe nausea before it begins.
“It’s going to be helpful as far as exploring new avenues for therapies and exploring ways to better predict, diagnose, treat and potentially prevent HG in the future.” — Marlena Fejzo, Lead Researcher
Conclusion
By pinpointing GDF15 as a central driver of hyperemesis gravidarum, this study transforms our understanding of the condition from a vague hormonal sensitivity to a specific, genetically-driven disorder, paving the way for the first targeted medical treatments for HG.
